Supernus executive exercises 750 performance share units

SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin reported equity award activity involving Performance Share Units and common stock.

Rhea-AI Filing Summary

SUPERNUS PHARMACEUTICALS, INC. senior vice president and chief medical officer Jonathan Rubin reported equity award activity involving Performance Share Units and common stock. On August 12, 2026, 750 Performance Share Units were exercised and converted into 750 shares of common stock at a conversion price of $0.00 per share, following the achievement of individual performance objectives described in an award granted on February 19, 2025 and performance objectives established on May 3, 2025.

Of the common shares underlying this vesting, 363 shares of common stock were withheld by the company at a price of $46.57 per share to satisfy tax withholding requirements related to the vesting. Footnote disclosure also states that the reporting person’s direct holdings include an aggregate of 251 shares acquired through the issuer’s Employee Stock Purchase Plan.

Insider Trade Summary

750 shares exercised/converted

Exercise 3 txns

Insider Rubin Jonathan

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Performance Share Unit F3	750	$0.00	$0.00
Exercise	Common Stock F1	750	$0.00	$0.00
Tax Withholding	Common Stock F2	363	$46.57	$17K

Holdings After Transaction: Performance Share Unit — 0 contracts (Direct); Common Stock — 13,979 shares (Direct)

Footnotes (3)

1. F1. Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
2. F2. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
3. F3. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Key Figures

Performance Share Units exercised: 750 units Common shares acquired from PSU vesting: 750 shares Shares withheld for tax withholding: 363 shares +4 more

7 metrics

Performance Share Units exercised 750 units Performance Share Units converted into common stock on August 12, 2026

Common shares acquired from PSU vesting 750 shares Shares of common stock received upon PSU conversion on August 12, 2026

Shares withheld for tax withholding 363 shares Common stock withheld by company to satisfy tax withholding requirements

Tax withholding share price $46.57 per share Price used for shares withheld to satisfy tax withholding obligations

ESPP shares included in holdings 251 shares Aggregate shares acquired through Employee Stock Purchase Plan included in holdings

PSU award grant date February 19, 2025 Grant date of Performance Share Units that later vested and converted

Performance objectives established date May 3, 2025 Date individual performance objectives for the PSU award were established

Key Terms

Performance Share Units, Employee Stock Purchase Plan, tax withholding requirements, derivative security

4 terms

Performance Share Units financial

"On February 19, 2025, the Reporting Person was awarded Performance Share Units"

Performance share units are a type of company stock award given to employees that depend on the company meeting specific goals or targets. If these goals are achieved, the employee receives shares or the value of shares; if not, they may receive little or no compensation. This aligns employees’ interests with the company's success and encourages performance that benefits investors.

Employee Stock Purchase Plan financial

"Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

tax withholding requirements financial

"withheld by the Company to satisfy tax withholding requirements in connection with the vesting"

derivative security financial

"transaction_code_description":"Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SUPN executive Jonathan Rubin report in this Form 4 transaction?

Jonathan Rubin reported the exercise of 750 Performance Share Units into 750 shares of Supernus Pharmaceuticals common stock on August 12, 2026, with part of the resulting shares withheld by the company to cover tax withholding requirements.

How many Performance Share Units did SUPN’s Jonathan Rubin have vest and convert?

Jonathan Rubin had 750 Performance Share Units vest and convert into 750 shares of common stock. These units were granted on February 19, 2025, with performance objectives established on May 3, 2025, and a portion later satisfied through share withholding for taxes.

What was the purpose of the 363 SUPN shares reported with code F?

The 363 shares reported with transaction code F represent common stock withheld by Supernus Pharmaceuticals at $46.57 per share to satisfy tax withholding obligations triggered by the vesting of Performance Share Units, rather than an open-market sale.

Did SUPN’s Jonathan Rubin acquire or dispose of shares overall in this filing?

The filing shows both acquisitions and dispositions. Rubin acquired common stock through the exercise of 750 Performance Share Units, while 363 shares were disposed of by being withheld by the company for tax withholding related to the vesting event.

What additional holdings detail is disclosed for SUPN’s Jonathan Rubin?

A footnote states that Rubin’s direct holdings include 251 shares acquired through Supernus Pharmaceuticals’ Employee Stock Purchase Plan. This provides context on part of his existing common stock position but not a complete total holding figure.

Were SUPN Form 4 transactions by Jonathan Rubin under a Rule 10b5-1 plan?

The Form 4 indicates the document-level Rule 10b5-1 checkbox is not affirmatively checked. The footnotes describing these Performance Share Unit transactions do not state that they were executed pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:12 PM Accepted by SEC EDGAR 08/14/2026 - 05:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Jonathan

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2026		M		750	A	$0	14,342(1)	D
Common Stock	08/12/2026		F(2)		363	D	$46.57	13,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Unit	$0	08/12/2026		M			750	(3)	(3)	Common Stock	750	$0	0	D

Explanation of Responses:

1. Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

2. Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

3. On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)